Clinical trials: Epileptic
Epilepsy
Epilepsy Adherence in Children and Technology (eACT)
Fifty-eight percent of children with new-onset epilepsy do not take their antiepileptic drugs (AEDs) as prescribed, which is associated with continued seizures, mortality, poor quality of life, and high healthcare costs.
- Trial name
- eACT (NCT03817229)
- Testing
- Education microlearning sessions, Automated digital reminders, Problem-solving mHealth module
- Where
- 4 sites in United States
- Volunteers
- 268 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Autism Spectrum Disorder, EEG With Periodic Abnormalities
Safety and Efficacy of tPBM for Epileptiform Activity in Autism
For this study, the proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children with abnormal EEGs with epileptiform discharges or…
- Conditions
- Autism Spectrum Disorder, EEG With Periodic Abnormalities, Epilepsy, Neurodevelopmental Disorders
- Trial name
- tPBM (NCT06352372)
- Testing
- noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Richard Frye
Epilepsy
Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093
Single centre, open-label, randomised, three-way crossover study in 18 healthy subjects (9 males and 9 females). The study consisted of three consecutive single-dose treatment periods separated by a washout period of 7 days or…
- Trial name
- NCT02279667
- Testing
- BIA 2-093
- Where
- Portugal
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy
A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994
Study is conducted to evaluate the long-term safety and tolerability of lacosamide (LCM) in patients receiving LCM in SP0994 [NCT01465997].
- Trial name
- NCT02582866
- Testing
- Lacosamide
- Where
- 46 sites in Bulgaria, Finland and 13 more
- Volunteers
- 106 people
- Sponsor
- UCB Biopharma S.P.R.L.
Epilepsy
Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?
Many patients with epilepsy have memory deficits in the setting of otherwise normal intelligence. Unfortunately, the treatment options for memory dysfunction in patients with epilepsy are limited.
- Trial name
- NCT01054599
- Testing
- Memantine, Sugar Pill
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- American Academy of Neurology
Epilepsy With Partial-onset Seizures
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
The purpose of this trial is to assess the efficacy, safety and tolerability of lacosamide administered as add-on therapy with 1 to 3 anti-seizure medications.
- Trial name
- NCT02477839
- Testing
- Lacosamide
- Where
- 88 sites in United States, Argentina and 24 more
- Volunteers
- 255 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy
Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures
The purpose of this study is to determine if Omega-3 fatty acids reduce seizures and modify cardiac risk factors in people with epilepsy.
- Trial name
- FOS (NCT00871377)
- Testing
- High Dose Fish Oil, Low Dose Fish Oil
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Epilepsy
Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern
This is a multi-center, double-blind, randomized, parallel group, dose-ranging study to investigate the efficacy and clinical usability of STAP-001 in adult (18 years of age and older) subjects with epilepsy with a predictable…
- Trial name
- StATES (NCT03478982)
- Testing
- Staccato Alprazolam
- Where
- 67 sites in United States, Australia and 1 more
- Volunteers
- 156 people
- Sponsor
- Engage Therapeutics, Inc.
Chronic Urticaria
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
This study evaluated the safety and efficacy of omalizumab in adult patients with moderate to severe chronic urticaria who exhibit IgE against thyroperoxidase.
- Trial name
- NCT00481676
- Testing
- Omalizumab 75-375 mg, Loratadine, Clemastine
- Where
- 11 sites in Germany
- Volunteers
- 49 people
- Sponsor
- Novartis
Epilepsy
Feasibility Study on LITT for Medical Refractory Epilepsy
Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System for the treatment of drug-refractory medial…
- Trial name
- NCT02820740
- Testing
- NeuroBlate System
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Monteris Medical
Seizures
Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures
This is a Phase IV adjunctive treatment dose-optimization study evaluating the efficacy, safety, and health outcomes of ezogabine/retigabine immediate release (IR) (GW582892) compared with placebo in adult subjects with…
- Trial name
- NCT01721317
- Testing
- Ezogabine/Retigabine IR
- Where
- 11 sites in United States, Greece
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Epilepsy
An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures
This is a multicentre, open label study to examine the effect of ezogabine/retigabine on the voiding function of adult subjects with drug-resistant partial onset seizures (POS).
- Trial name
- NCT01607346
- Testing
- ezogabine/retigabine
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Epilepsy
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
Trial N01395 is to evaluate the reduction of nonpsychotic behavioral side effects in subjects with Epilepsy who switched to BRV 200 mg/day after discontinuing LEV due to such side effects; as well as the efficacy, safety and…
- Trial name
- NCT01653262
- Testing
- Brivaracetam
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 29 people
- Sponsor
- UCB Pharma SA
Seizure Disorder, Hypogonadism
Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo
The purpose of this study is to determine if treatment using a medication (anastrozole/Arimidex), which lowers estrogen levels in the blood is better than placebo, a tablet that does not contain any active medication, when…
- Conditions
- Seizure Disorder, Hypogonadism, Erectile Dysfunction
- Trial name
- NCT00179517
- Testing
- Anastrozole 1mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Beth Israel Deaconess Medical Center
Epilepsy
Staccato Alprazolam and Photoparoxysmal Response
The purpose of this study is to determine whether people who usually have photosensitive epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato Alprazolam as compared to placebo.
- Trial name
- NCT02351115
- Testing
- B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 m, D= Inhaled Alprazolam 2 mg
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nova Pneuma Inc.
Epilepsy
Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
The purpose of this study is to determine the effects of age on the pharmacokinetic profile of BIA 2-093 and its active metabolites.
- Trial name
- NCT02172755
- Testing
- BIA 2-093
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsies, Partial
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months.
- Trial name
- NCT00351611
- Testing
- Lyrica (pregabalin)
- Where
- 150 sites in United States, Bulgaria and 7 more
- Volunteers
- 187 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Platelet Aggregation, Spontaneous, Migraine With Aura
pLatelEts And MigRaine iN patEnt foRamen Ovale
Migraine is a common, chronic neurovascular disorder characterized by attacks of severe headache, autonomic nervous system dysfunction and, in some patients, aura, and disabling neurological symptoms.
- Conditions
- Platelet Aggregation, Spontaneous, Migraine With Aura, Patent Foramen Ovale
- Trial name
- LEARNER (NCT03521193)
- Testing
- patent foramen ovale closure
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Centro Cardiologico Monzino
Mesial Temporal Lobe Epilepsy
Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)
The primary aim of the current proposal is to evaluate safety and tolerability, in terms of neuropsychological effects of low frequency electrical stimulation of the fornix (LFSF) in participants with medically-intractable Mesial…
- Trial name
- MTLE-DBS (NCT02383407)
- Testing
- Medtronic Deep Brain Stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- George Washington University
Epilepsy
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
This Phase 3, multicenter, open-label study of chronic, intermittent use of study drug (DBF) is designed to evaluate the safety and tolerability of the buccal formulation of diazepam in children, adolescents and adults with…
- Trial name
- DBF (NCT03428360)
- Testing
- Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
- Where
- 6 sites in United States
- Volunteers
- 149 people
- Sponsor
- Aquestive Therapeutics